Damora Therapeutics, Inc. (DMRA) annual income statement — 8-year revenue, gross profit & net income history
Damora Therapeutics, Inc. (DMRA) annual income statement — 8-year revenue, gross profit & net income history
| Metric | TTM | Dec'25 | Dec'24 | Dec'23 | Dec'22 | Dec'21 | Dec'20 | Dec'19 | Dec'18 |
|---|
| Sales/Revenue | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Revenue Growth % | - | - | - | - | - | - | - | - | - |
| Cost of Goods Sold | 79K | 0 | 181K | 830K | 490K | 441K | 188K | 111K | 0 |
| COGS % of Revenue | - | - | - | - | - | - | - | - | - |
| Gross Profit | -79K | 0 | -181K | -830K | -490K | -441K | -188K | -111K | 0 |
| Gross Margin % | - | - | - | - | - | - | - | - | - |
| Gross Profit Growth % | - | 100% | 78.19% | -69.39% | -11.11% | -134.57% | -69.37% | - | - |
| Operating Expenses | 304.29M | 210.87M | 16.72M | 35.63M | 60.72M | 51.79M | 33.45M | 38.86M | 12.91M |
| OpEx % of Revenue | - | - | - | - | - | - | - | - | - |
| Selling, General & Admin | 31.93M | 9.69M | 10.32M | 11.86M | 12.51M | 13.3M | 8.82M | 2.33M | 2.81M |
| SG&A % of Revenue | - | - | - | - | - | - | - | - | - |
| Research & Development | 272.42M | 201.19M | 6.4M | 23.77M | 48.21M | 38.49M | 24.63M | 36.53M | 10.09M |
| R&D % of Revenue | - | - | - | - | - | - | - | - | - |
| Other Operating Expenses | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating Income | -304.36M | -210.87M | -16.9M | -36.46M | -61.21M | -52.23M | -33.64M | -38.97M | -12.91M |
| Operating Margin % | - | - | - | - | - | - | - | - | - |
| Operating Income Growth % | - | -1147.98% | 53.65% | 40.44% | -17.19% | -55.27% | 13.69% | -201.94% | - |
| EBITDA | -304.01M | -210.84M | -16.72M | -35.63M | -60.72M | -51.79M | -33.45M | -38.86M | -12.91M |
| EBITDA Margin % | - | - | - | - | - | - | - | - | - |
| EBITDA Growth % | -2465.3% | -1161.29% | 53.08% | 41.32% | -17.25% | -54.82% | 13.92% | -201.08% | - |
| D&A (Non-Cash Add-back) | 350K | 34K | 181K | 830K | 490K | 441K | 188K | 111K | 0 |
| EBIT | -300.29M | -209.79M | -21.4M | -38.35M | -61.62M | -51.75M | -33.64M | -38.97M | -12.91M |
| Net Interest Income | 12.29M | 1.17M | 844K | 1.69M | 722K | 156K | 0 | 0 | -2.97M |
| Interest Income | 12.29M | 1.17M | 844K | 1.69M | 722K | 156K | 0 | 0 | 0 |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2.97M |
| Other Income/Expense | 13.02M | 1.08M | -4.5M | -1.89M | -417K | 475K | -1.2M | 2.46M | -2.96M |
| Pretax Income | -291.34M | -209.79M | -21.4M | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M | -15.87M |
| Pretax Margin % | - | - | - | - | - | - | - | - | - |
| Income Tax | 341K | 50K | 41K | 0 | 0 | 0 | 0 | 0 | 0 |
| Effective Tax Rate % | -0.12% | -0.02% | -0.19% | 0% | 0% | 0% | 0% | 0% | 0% |
| Net Income | -291.68M | -209.84M | -21.44M | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M | -15.87M |
| Net Margin % | - | - | - | - | - | - | - | - | - |
| Net Income Growth % | -1740.97% | -878.77% | 44.09% | 37.77% | -19.08% | -48.55% | 4.57% | -130.05% | - |
| Net Income (Continuing) | -291.68M | -209.84M | -21.44M | -38.35M | -61.62M | -51.75M | -34.84M | -36.51M | -15.87M |
| Discontinued Operations | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Minority Interest | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| EPS (Diluted) | -17.82 | -152.99 | -18.53 | -36.08 | -60.63 | -51.22 | -34.48 | -41.35 | -18.68 |
| EPS Growth % | -915.04% | -725.63% | 48.64% | 40.49% | -18.37% | -48.55% | 16.61% | -121.36% | - |
| EPS (Basic) | - | -152.99 | -18.53 | -36.08 | -60.63 | -51.22 | -34.48 | -41.35 | -18.68 |
| Diluted Shares Outstanding | 16.37M | 1.36M | 1.16M | 1.06M | 1.02M | 1.01M | 1.01M | 1.02M | 1.02M |
| Basic Shares Outstanding | 16.37M | 1.36M | 1.16M | 1.06M | 1.02M | 1.01M | 1.01M | 1.02M | 1.02M |
| Dividend Payout Ratio | - | - | - | - | - | - | - | - | - |
Quick answers to the most common questions about buying DMRA stock.
For fiscal year 2025, Damora Therapeutics, Inc. (DMRA) reported total revenue of $0.0M.
Damora Therapeutics, Inc. (DMRA) reported a net loss of $209.8M for the fiscal year ending 2025.